Modified Macrolides with Halogenated Desosamine for Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics are ineffective against drug-resistant Gram-negative bacteria, with emerging resistance and a lack of new antibiotic development, particularly in nosocomial settings, leading to increased healthcare costs and mortality.
Innovation Solution
Development of macrolides with modified sugars at the C5 position, specifically modifying the C6 position of desosamine, to enhance antibacterial activity against resistant strains, including Gram-negative bacteria, through structural modifications that improve binding to ribosomal RNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If macrolides undergo acid-promoted internal ketalization (cyclization of C6 and C12 hydroxyl groups onto C9 ketone), then the macrolides can be synthesized, but adverse gastrointestinal events occur
Solution Approach 1:
The patent removes the problematic C6 hydroxyl group involved in acid-promoted cyclization by replacing it with a halogen atom (chloro or fluoro substituent). This extraction of the harmful functional group prevents the formation of the cyclic ketal that causes gastrointestinal distress while preserving the macrolide core structure and its antibacterial activity.
Solution Approach 2:
The patent converts the potentially harmful C6 hydroxyl group into a beneficial halogen substituent. The chloro or fluoro group at C6 not only prevents the harmful cyclization reaction but also enhances the antibacterial activity against Gram-negative bacteria, transforming a source of side effects into a feature that improves therapeutic efficacy.
2Reliability
If existing antibiotics are used, then treatment of infections is provided, but effectiveness against drug-resistant Gram-negative bacteria is lost
Solution Approach 1:
The patent applies local quality modification by introducing specific halogen substituents at the C6 position of the desosamine sugar moiety. This localized chemical modification at a specific position enhances the molecule's ability to interact with bacterial ribosomes in Gram-negative bacteria, providing targeted improvement in activity against resistant strains without altering the entire macrolide structure.
Solution Approach 2:
The patent changes the chemical parameter at the C6 position from a hydroxyl group to a halogen atom (chlorine or fluorine). This parameter change modifies the electronic and steric properties of the molecule, enabling it to overcome resistance mechanisms in Gram-negative bacteria while maintaining compatibility with the macrolide binding site in the bacterial ribosome.
3Reliability
If macrolides are modified to improve activity against Gram-negative bacteria, then antibacterial efficacy is enhanced, but structural complexity increases
Solution Approach 1:
The patent employs local quality modification by introducing substituents at only one specific position (C6 of desosamine) rather than making comprehensive modifications throughout the molecule. This focused approach achieves enhanced Gram-negative coverage while minimizing the increase in overall molecular complexity and maintaining ease of semi-synthetic production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified macrolides demonstrate potent activity against drug-resistant Gram-negative bacteria, offering a potential solution to the growing antibiotic resistance crisis by enhancing binding affinity and reducing side effects.
Implementation Method 1
modifying the C6 position of desosamine to enhance antibacterial activity against resistant strains, including Gram-negative bacteria, through structural modifications that improve binding to ribosomal RNA
Data Source
AI summary
Provided are macrolide compounds for the treatment of infectious diseases. The macrolides disclosed herein include 14-membered ketolides and 14-15-membered azaketolides, and may comprise modified sugars which are desosamine analogues. The disclosed macrolides may have a bicyclic structure. Also provided are pharmaceutical compositions and methods of treating infectious diseases, and in particular, disease which results from Gram negative bacteria using the disclosed macrolides. This disclosure additionally provides methods of preparing the macrolides by a strategy that enables late-stage modification of the 6′-position of the sugar moiety, thereby allowing facile access to previously difficult-to-make macrolide compounds.